Koji Takei
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.
Journal: Muscle & nerve
Published: December 11, 2020
Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: April 16, 2019
Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 06, 2017
An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 06, 2017
Edaravone and its clinical development for amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 06, 2017
Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 06, 2017
Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 06, 2017
Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 06, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026